Management of the clinically node-negative axilla in primary breast cancer

Abdul Q. Alarhayem, Ismail Jatoi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Axillary lymph node status is an important prognostic factor in patients with primary breast cancer. Yet, management of the axilla in these patients has been controversial. Sentinel lymph node biopsy (SLNB) is a less morbid procedure with similar survival and recurrence when compared to axillary lymph node dissection (ALND) and has emerged as the standard of care for staging patients with clinically node-negative disease. The results of three randomized trials seem to suggest that completion ALND may not be necessary in all women with T1/T2 tumors that have sentinel node-positive tumors and a low burden of axillary disease. However, while patients with isolated tumor cells or micrometastatic disease in the sentinel node may forego further axillary treatment, we believe that those with macrometastatic disease on SLNB should undergo additional axillary treatment (either ALND or radiotherapy) until further evidence defining which patients may benefit from observation alone emerges.

Original languageEnglish (US)
Title of host publicationPersonalized Treatment of Breast Cancer
PublisherSpringer Japan
Pages103-117
Number of pages15
ISBN (Electronic)9784431555520
ISBN (Print)9784431555513
DOIs
StatePublished - Jan 1 2016

Keywords

  • Axilla
  • Breast cancer
  • Radiotherapy
  • Surgery

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Management of the clinically node-negative axilla in primary breast cancer'. Together they form a unique fingerprint.

Cite this